comparemela.com

Latest Breaking News On - சிகிச்சை ஓபியாய்டு பயன்பாடு கோளாறு - Page 1 : comparemela.com

HHS Issues Buprenorphine Practice Guidelines as Study Confirms Access Barriers | Mintz - Health Care Viewpoints

Dept of Health Buprenorphine for Treating Opioid Use Disorder Guidance

Wednesday, June 9, 2021 One of the spillover effects of the COVID-19 pandemic has been the increase in opioid-related deaths. These deaths overwhelmingly affect working-class Americans with limited access and resources to lifesaving drugs such as buprenorphine and naloxone. As a result, the Department of Health and Human Services (HHS) issued the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder (Practice Guidelines) through a waiver of certain certification requirements prescribed by law. The Practice Guidelines remove a longtime prerequisite tied to training and counseling that several practitioners have cited as a barrier to treating patients with Opioid Use Disorder (OUD). The Practice Guidelines could not come soon enough, as a recent study indicates that individuals with OUD experienced decreased access to treatments during the pandemic.

Overcoming Barriers to Treatment of Opioid Use Disorder | Substance Use and Addiction | JAMA

On January 14, 2021, days before a change in presidential administrations, the US Department of Health and Human Services (HHS) announced a plan to publish Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder “pursuant to 21 USC §823(g)(2)(H)(i)(II),” a provision of the Drug Addiction and Treatment Act of 2000 (DATA 2000). 1 This announcement caused a mix of enthusiasm, skepticism, and confusion in the medical community, and the retraction of the plan to publish the guideline less than 2 weeks later by the Biden administration has created an opportunity for fundamental and needed reform. DATA 2000 was a major change in the treatment of addiction. For the first time since 1914, the law allowed physicians to prescribe an approved opioid agonist medication for the treatment of opioid use disorder (OUD) as part of general medical practice, provided these physicians met certain training and practice certification requirements, notified the Su

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.